Ipamorelin
Growth hormone secretagogue (ghrelin/growth hormone secretagogue receptor agonist)
Quick Answer
A synthetic peptide designed to stimulate growth hormone release via the ghrelin receptor pathway, often discussed alongside CJC-1295 in research/community contexts as a combination.
Why People Are Interested
Discussed as the "gentler" growth-hormone secretagogue — its proposed selectivity for GH release over cortisol and other hormones is the specific reason it comes up so often as an alternative to older compounds in this class.
What People Hope It May Do
GH-release benefits for body composition and recovery with fewer side effects than older secretagogues, based on an early pharmacological selectivity argument. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Growth hormone secretion selectivity
Potential body-composition and recovery-related research questions (largely community-driven interest)
How It May Work
Activates the growth hormone secretagogue receptor, prompting pulsatile growth hormone release from the pituitary, with a proposed selectivity profile intended to minimize effects on other hormones (e.g., cortisol) compared to older secretagogues — this selectivity claim originates in early pharmacology research and should be attributed and hedged accordingly, not stated as settled fact.
What Human Research Shows
One verified human trial exists (Beck et al. 2014, see Key studies) — a Phase 2 trial in postoperative ileus patients, an indication unrelated to growth-hormone secretion or the compound's proposed selectivity. Its primary endpoint was not statistically significant. No human trial verified to date tests the GH-secretion or hormone-selectivity claims directly; those remain supported only by animal data (see Proposed mechanism and Key studies).
What Preclinical Research Shows
Receptor-binding and endocrine pharmacology studies form the bulk of the available preclinical picture.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to Ipamorelin is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving Ipamorelin, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
No comprehensive controlled human safety database exists publicly at drug-approval scale. General hormone-axis manipulation carries risks that require licensed medical supervision to assess — not something to characterize as safe or unsafe in a general-audience article without that caveat.
Regulatory Status
Not FDA-approved as a standalone product for any indication.
What We Still Don't Know
Whether that selectivity claim holds up in large, independent human trials, and what the real-world tradeoffs of sustained use look like.
Limitations of Evidence
Sparse controlled human trials; much of the public discussion is anecdotal rather than clinical-trial-derived.
Keep Researching
- Search ClinicalTrials.gov for Ipamorelin
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Key Studies
Two distinct sources, verified separately via NCBI eutils on 2026-10-11 — do not conflate them, as they answer different questions. (1) Selectivity claim, PMID 9849822: Raun K, Hansen BS, Johansen NL, et al., European Journal of Endocrinology, 1998 — an ANIMAL study (rats and swine), not human. Found ipamorelin released GH without significantly raising ACTH or cortisol (unlike GHRP-2/GHRP-6), even at 200x the GH-effective dose, and had no effect on FSH/LH/prolactin/TSH. This is the actual origin of the "selectivity" claim in Proposed mechanism above — it has never been confirmed in a comparable human trial. (2) Human trial, PMID 25331030: Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group, International Journal of Colorectal Disease, 2014 — a real, multicenter, double-blind, placebo-controlled Phase 2 trial (n=114) for postoperative ileus after bowel resection, not GH-axis selectivity. Primary endpoint (time to tolerated solid meal) was 25.3h (ipamorelin) vs. 32.6h (placebo), P=0.15 — not statistically significant. This is the only verified human trial of ipamorelin; it does not support the GH-elevation or selectivity claims, only that ipamorelin has been dosed in real human patients and was reported as well tolerated.
References
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. PMID: 9849822. Verified via NCBI eutils abstract fetch, 2026-10-11. Animal (rat/swine) study — not human data.
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients." International Journal of Colorectal Disease. 2014;29(12):1527-1534. PMID: 25331030. Verified via NCBI eutils abstract fetch, 2026-10-11.
Last reviewed: 2026-10-11 (Key studies/References added, Human evidence corrected, and independently verified — see note above)
Last reviewed: 2026-10-11 (Key studies/References added, Human evidence corrected, and independently verified — see note above)
